Study summary

Two immunotherapies kept most MSI-high metastatic cancers in check for 2 years

CheckMate 8HW trial (nivolumab plus ipilimumab) · 303 people in this comparison, phase 3 · Published November 2024, New England Journal of Medicine

72%without progression at 2 years, vs 14% with chemotherapy

What was tested

Nivolumab plus ipilimumab against chemotherapy as first treatment for metastatic MSI-high or dMMR colorectal cancer.

What they found

What it means

Immunotherapy is now the first treatment for MSI-high metastatic colorectal cancer.

N Engl J Med, via PubMed ↗ Trial record NCT04008030 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.